Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apo Baclofen
2. Apo-baclofen
3. Apobaclofen
4. Atrofen
5. Awd, Baclofen
6. Ba-34,647
7. Ba-34647
8. Ba34,647
9. Ba34647
10. Baclofne Irex
11. Baclofne-irex
12. Baclofneirex
13. Baclofen Awd
14. Baclophen
15. Baclospas
16. Beta-(aminomethyl)-4-chlorobenzenepropanoic Acid
17. Beta-(p-chlorophenyl)-gamma-aminobutyric Acid
18. Chlorophenyl Gaba
19. Ciba-34,647-ba
20. Ciba34,647ba
21. Clofen
22. Gaba, Chlorophenyl
23. Gen Baclofen
24. Gen-baclofen
25. Genbaclofen
26. Genpharm
27. Lebic
28. Liorsal
29. Lioresal
30. Nu Baclo
31. Nu-baclo
32. Nubaclo
33. Pcp-gaba
34. Pms Baclofen
35. Pms-baclofen
36. Pmsbaclofen
1. 1134-47-0
2. Lioresal
3. 4-amino-3-(4-chlorophenyl)butanoic Acid
4. Kemstro
5. Baclon
6. Dl-baclofen
7. Gabalon
8. (+-)-baclofen
9. Baclofene
10. Baclofeno
11. Baclofenum
12. (rs)-baclofen
13. Beta-(4-chlorophenyl)gaba
14. 4-amino-3-(4-chlorophenyl)butyric Acid
15. Ba-34647
16. Gablofen
17. Ciba 34,647-ba
18. (+/-)-baclofen
19. Dl-4-amino-3-p-chlorophenylbutanoic Acid
20. Beta-(aminomethyl)-4-chlorobenzenepropanoic Acid
21. Ba-34,647
22. Beta-(p-chlorophenyl)-gamma-aminobutyric Acid
23. Baclofen (r,s)
24. C 34647ba
25. Ba 34647
26. Beta-(aminomethyl)-p-chlorohydrocinnamic Acid
27. Gamma-amino-beta-(p-chlorophenyl)butyric Acid
28. Butanoic Acid, 4-amino-3-(4-chlorophenyl)-
29. Mfcd00055143
30. Chembl701
31. Nsc-755906
32. Benzenepropanoic Acid, Beta-(aminomethyl)-4-chloro-
33. Chebi:2972
34. H789n3fke8
35. (+)-baclofen; (l)-baclofen
36. Atrofen
37. Baclophen
38. Lioresal Intrathecal
39. Apo-baclofen
40. Ncgc00015156-11
41. (rs)-amino-3-(4-chlorophenyl)butyric Acid
42. Dsstox_cid_2641
43. 4-amino-3(4-chlorophenyl)butyric Acid
44. Baclofene [inn-french]
45. Baclofenum [inn-latin]
46. .beta.-(aminomethyl)-p-chlorohydrocinnamic Acid
47. Dsstox_rid_76670
48. Baclofeno [inn-spanish]
49. Dsstox_gsid_22641
50. .beta.-(aminomethyl)-4-chlorobenzenepropanoic Acid
51. Lioresal (tn)
52. Kemstro (tn)
53. Ccris 3722
54. Sr-01000000107
55. Einecs 214-486-9
56. Brn 2104494
57. Unii-h789n3fke8
58. Baclofen O
59. Ipx056
60. Mfcd01321057
61. Ipx 056
62. (y)-baclofen
63. Prestwick_85
64. Cas-1134-47-0
65. (?)-baclofen
66. Fleqsuvy
67. Lyvispah
68. Ozobax
69. Baclofen [usan:usp:inn:ban:jan]
70. (a+/-)-baclofen
71. Spectrum_000066
72. Baclofen [usan]
73. Baclofen [inn]
74. Baclofen [jan]
75. Baclofen [mi]
76. Baclofen [vandf]
77. (.+/-.)-baclofen
78. (.+/-.)-baklofen
79. Prestwick0_000085
80. Prestwick1_000085
81. Prestwick2_000085
82. Prestwick3_000085
83. Spectrum2_000092
84. Spectrum3_000310
85. Spectrum4_000245
86. Spectrum5_000852
87. Baclofen-[d4] (major)
88. Baclofen [mart.]
89. Baclofen [usp-rs]
90. Baclofen [who-dd]
91. Biomol-nt_000251
92. Upcmld-dp142
93. (±)-baclofen
94. B 5399
95. Lopac0_000163
96. Oprea1_440627
97. Schembl19333
98. Bspbio_000010
99. Bspbio_001880
100. Kbiogr_000650
101. Kbioss_000466
102. Mls000028480
103. .beta.-(4-chlorophenyl)gaba
104. Divk1c_000001
105. Spectrum1500135
106. Baclofen (jp17/usp/inn)
107. Hydrocinnamic Acid, .beta.-(aminomethyl)-p-chloro-
108. Spbio_000044
109. Spbio_001949
110. Baclofen [orange Book]
111. Benzenepropanoic Acid, .beta.-(aminomethyl)-4-chloro-
112. Bpbio1_000012
113. Bpbio1_000750
114. Gtpl1084
115. Baclofen [ep Monograph]
116. Baclofen [usp Monograph]
117. Dtxsid5022641
118. Hydrocinnamic Acid, Beta-(aminomethyl)-p-chloro-
119. Upcmld-dp142:001
120. Bdbm24182
121. Hms500a03
122. Kbio1_000001
123. Kbio2_000466
124. Kbio2_003034
125. Kbio2_005602
126. Kbio3_001380
127. Baclofen 0.5 Mg/ml In Methanol
128. Ninds_000001
129. Hms1568a12
130. Hms1920e21
131. Hms2091m03
132. Hms2095a12
133. Hms3260b07
134. Hms3712a12
135. Pharmakon1600-01500135
136. ( Inverted Question Mark)-baclofen
137. Albb-014712
138. Bcp11844
139. Bcp32777
140. Ex-a1378
141. Hy-b0007
142. Tox21_110090
143. Tox21_500163
144. Bbl010735
145. Ccg-38910
146. Cx1358
147. Nsc329137
148. Nsc755906
149. S4840
150. Stk535284
151. Akos005174692
152. Tox21_110090_1
153. Ac-4530
154. Db00181
155. Hs-1001
156. Lp00163
157. Mb00475
158. Nsc 755906
159. Nsc-329137
160. Sb67382
161. Sdccgsbi-0050151.p005
162. 4-amino-3-(4-chlorophenyl)butanoicacid
163. 4-amino-3-(p-chlorophenyl)butyric Acid
164. Idi1_000001
165. Smp1_000036
166. Ncgc00015156-04
167. Ncgc00015156-05
168. Ncgc00015156-06
169. Ncgc00015156-07
170. Ncgc00015156-08
171. Ncgc00015156-12
172. Ncgc00015156-13
173. Ncgc00015156-15
174. Ncgc00015156-26
175. Ncgc00015156-28
176. Ncgc00023843-03
177. Ncgc00024579-03
178. Ncgc00024579-04
179. Ncgc00024579-05
180. Ncgc00024579-06
181. Ncgc00260848-01
182. Bb166152
183. Smr000058294
184. Sy023865
185. Sy052300
186. Sbi-0050151.p004
187. (+/-)-baclofen, >=98% (tlc), Solid
188. 4-amino-3-(4-chlorophenyl)butanoic Acid #
189. Ab00051921
190. Eu-0100163
191. Ft-0622547
192. Ft-0662468
193. Ft-0662469
194. (rs)-4-amino-3-(4-chlorophenyl)butanoic Acid
195. D00241
196. Ab00051921_16
197. .beta.-(p-chlorophenyl)-.gamma.-aminobutyric Acid
198. .gamma.-amino-.beta.-(p-chlorophenyl)butyric Acid
199. 134b470
200. L000002
201. Q413717
202. J-002965
203. Sr-01000000107-2
204. Sr-01000000107-4
205. Sr-01000000107-6
206. Sr-01000000107-8
207. Brd-a84174873-001-05-2
208. (+/- )-beta-(aminomethyl)-4-chlorobenzenepropanoic Acid
209. Baclofen, British Pharmacopoeia (bp) Reference Standard
210. Baclofen, European Pharmacopoeia (ep) Reference Standard
211. F2173-1127
212. Stx209; Stx-209; Stx 209; D-baclofen; Arbaclofen
213. Baclofen Lioresal 4-amino-3-(4-chlorophenyl)butyric Acid
214. Baclofen, United States Pharmacopeia (usp) Reference Standard
215. N-boc-(2s,3s)-2-hydroxy-3-amino-5-methylhexanoicacid
216. Baclofen, Pharmaceutical Secondary Standard; Certified Reference Material
217. Baclofen Solution, 500 Mug/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
218. Baclofen Solution, 500 Mug/ml (90:10 Meoh:dmso), Certified Reference Material, Ampule Of 1 Ml
219. Brivaracetam-d3 Solution, 100 Mug/ml In Methanol, Certified Reference Material, Ampule Of 1 Ml
Molecular Weight | 213.66 g/mol |
---|---|
Molecular Formula | C10H12ClNO2 |
XLogP3 | -1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 213.0556563 g/mol |
Monoisotopic Mass | 213.0556563 g/mol |
Topological Polar Surface Area | 63.3 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 191 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Baclofen |
PubMed Health | Baclofen |
Drug Classes | Analgesic, Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | LIORESAL INTRATHECAL (baclofen injection) is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen is a white to off-white, odorless or practically odorless crystal... |
Active Ingredient | Baclofen |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Watson Labs; Vintage Pharms; Mylan Pharms; Ivax Sub Teva Pharms; Caraco; Lannett; Usl Pharma; Sun Pharm Inds; Northstar Hlthcare; Prosam Labs; Mylan; Impax Labs |
2 of 6 | |
---|---|
Drug Name | Gablofen |
PubMed Health | Baclofen |
Drug Classes | Analgesic, Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Gablofen (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino- 3-(4-chlorophenyl) butanoic acid, and its structural for |
Active Ingredient | Baclofen |
Dosage Form | Injectable |
Route | Intrathecal |
Strength | 2mg/ml; 1mg/ml; 0.05mg/ml; 0.5mg/ml |
Market Status | Prescription |
Company | Mallinckrodt |
3 of 6 | |
---|---|
Drug Name | Lioresal |
PubMed Health | Baclofen (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | LIORESAL INTRATHECAL (baclofen injection) is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen is a white to off-white, odorless or practically odorless crystal... |
Active Ingredient | Baclofen |
Dosage Form | Injectable |
Route | Intrathecal |
Strength | 2mg/ml; 0.05mg/ml; 0.5mg/ml |
Market Status | Prescription |
Company | Medtronic Neuro |
4 of 6 | |
---|---|
Drug Name | Baclofen |
PubMed Health | Baclofen |
Drug Classes | Analgesic, Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | LIORESAL INTRATHECAL (baclofen injection) is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen is a white to off-white, odorless or practically odorless crystal... |
Active Ingredient | Baclofen |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Watson Labs; Vintage Pharms; Mylan Pharms; Ivax Sub Teva Pharms; Caraco; Lannett; Usl Pharma; Sun Pharm Inds; Northstar Hlthcare; Prosam Labs; Mylan; Impax Labs |
5 of 6 | |
---|---|
Drug Name | Gablofen |
PubMed Health | Baclofen |
Drug Classes | Analgesic, Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | Gablofen (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino- 3-(4-chlorophenyl) butanoic acid, and its structural for |
Active Ingredient | Baclofen |
Dosage Form | Injectable |
Route | Intrathecal |
Strength | 2mg/ml; 1mg/ml; 0.05mg/ml; 0.5mg/ml |
Market Status | Prescription |
Company | Mallinckrodt |
6 of 6 | |
---|---|
Drug Name | Lioresal |
PubMed Health | Baclofen (By mouth) |
Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
Drug Label | LIORESAL INTRATHECAL (baclofen injection) is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen is a white to off-white, odorless or practically odorless crystal... |
Active Ingredient | Baclofen |
Dosage Form | Injectable |
Route | Intrathecal |
Strength | 2mg/ml; 0.05mg/ml; 0.5mg/ml |
Market Status | Prescription |
Company | Medtronic Neuro |
Baclofen is indicated for the treatment of spasticity resulting from multiple sclerosis and is particularly useful for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. It may also be of value in the treatment of patients with spinal cord injuries or diseases. Baclofen is also indicated as an intrathecal injection for the management of severe spasticity of cerebral or spinal original in patients 4 years of age and older. Patients who respond to bolus intrathecal doses of baclofen, and who require chronic therapy, can use an implantable intrathecal pump to administer baclofen via long-term infusion.
FDA Label
Treatment of alcohol dependence
In neurological diseases associated with spasm of the skeletal muscles, the clinical effects of baclofen occur due to baclofen action on reflex muscle contractions and of significant relief from painful spasm, automatism, as well as clonus. Baclofen, when used as indicated, improves mobility, increasing levels of independence, and facilitates both passive and active physiotherapy. Baclofen also stimulates gastric acid secretion. GABA-B receptor activation by baclofen may produce protective neurological effects. Baclofen also possesses anti-inflammatory properties that may be of interest in the study of addiction treatment. Preclinical studies have shown that GABA-B receptors have roles in memory storage and retrieval, reward, motivation, mood, as well as anxiety. Neuroimaging studies in humans indicate that baclofen produces region-specific alterations in brain activity.
GABA-B Receptor Agonists
Endogenous compounds and drugs that bind to and activate GABA-B RECEPTORS. (See all compounds classified as GABA-B Receptor Agonists.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
M03BX01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BX - Other centrally acting agents
M03BX01 - Baclofen
Absorption
Rapidly and almost completely absorbed from the gastrointestinal tract. Absorption may be dose-dependent, being reduced with increased doses. Baclofen, when introduced directly into the intrathecal space, allows for effective CSF concentrations to be achieved with resulting plasma concentrations 100 times less than concentrations occurring with oral administration,.
Route of Elimination
Baclofen is rapidly and extensively eliminated from the body. There is significant intersubject variation in elimination rates. Baclofen is excreted mainly by the kidney as unchanged drug. Seventy to eighty (70 - 80%) of a dose is measured in the urine as unchanged drug. The remainder of the dose is excreted as unchanged drug in the feces or as metabolites in the urine and feces. Excretion is complete within 72 hours after administration.
Volume of Distribution
**Apparent volume of distribution**: 59 liters. Baclofen does not readily cross the blood-brain barrier.
Clearance
**Total systemic clearance**: 180 mL/min **Renal clearance**: 103 mL/min Baclofen is primarily excreted unchanged by the kidneys. It should be administered cautiously, and it may be necessary to reduce the dosage in patients with reduced renal function.
Approximately 15% of the dose is metabolized in the liver, mainly by deamination. In a clinical study with radiolabeled baclofen, approximately 85% of the dose was excreted unchanged in the urine and feces. The -hydroxy metabolite, 3-(p-chlorophenyl)-4-hydroxybutyric acid, is formed by the deamination of baclofen. Because baclofen is partially metabolized in the liver, patients with impaired liver function should be regularly monitored with liver function tests.
Elimination half-life: Approximately 5.5 hours.
The exact mechanism of action of baclofen is not fully understood at this time,. Many studies indicate that baclofen is a GABA-B receptor agonist,,,,. Despite this, there is no conclusive evidence that the effects of baclofen on GABA systems are involved in the production of its clinical effects. Baclofen is an effective and widely used antispastic agent with a spinal site of action. Its mechanism of action and pharmacological properties are different from the effects of other antispastic agents. In addition, baclofen has central sites of action, shown by its adverse event profile and general CNS depressant properties. GABA-B receptors interact with signal transduction pathways and neurotransmitter systems. Baclofen exerts an antinociceptive effect. The clinical significance of this warrants further research data for clarification. Baclofen depresses monosynaptic and polysynaptic reflex transmission, by various actions, and possibly including the stimulation of GABA-receptors. This stimulation results in the inhibition of excitatory neurotransmitter (glutamate and aspartate) release, which may normally contribute to pain and spasticity. Although baclofen is an analog of the inhibitory neurotransmitter gamma-amino-butyric acid (GABA), there are no conclusive data indicating GABA systems are involved in its clinical effects.
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-08
Pay. Date : 2012-12-11
DMF Number : 18014
Submission : 2005-01-20
Status : Active
Type : II
Registration Number : 230MF10014
Registrant's Address : 19 Pellinska Str. 83-200 Starogard Gdanski POLAND
Initial Date of Registration : 2018-01-30
Latest Date of Registration :
NDC Package Code : 12658-0448
Start Marketing Date : 1977-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Wooshin Labotech Co., Ltd.
Registration Date : 2019-08-02
Registration Number : 20181018-209-J-161(5)
Manufacturer Name : Pharmaceutical Works Polpharma S.A.
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Available Reg Filing : ASMF, CA |
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-04
Pay. Date : 2013-09-30
DMF Number : 7077
Submission : 1987-07-14
Status : Active
Type : II
Certificate Number : R1-CEP 2003-247 - Rev 01
Issue Date : 2020-07-30
Type : Chemical
Substance Number : 653
Status : Valid
NDC Package Code : 51014-7035
Start Marketing Date : 2009-08-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, BR, CA |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6421
Submission : 1986-06-18
Status : Active
Type : II
NDC Package Code : 48954-641
Start Marketing Date : 1997-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-29
Pay. Date : 2018-11-26
DMF Number : 33302
Submission : 2018-11-09
Status : Active
Type : II
Certificate Number : CEP 2018-280 - Rev 02
Issue Date : 2025-01-22
Type : Chemical
Substance Number : 653
Status : Valid
Date of Issue : 2022-07-07
Valid Till : 2025-07-21
Written Confirmation Number : WC-0150
Address of the Firm :
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2021-06-29
Registration Number : 20210629-209-J-1043
Manufacturer Name : Cohance Lifesciences Limited
Manufacturer Address : RS 50/1, Mukteswarapuram Village, Jaggaiahpeta Mandal, Krishna District-521 175. Andhra Pradesh, India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
Certificate Number : R1-CEP 2003-247 - Rev 01
Status : Valid
Issue Date : 2020-07-30
Type : Chemical
Substance Number : 653
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Certificate Number : CEP 2018-280 - Rev 02
Status : Valid
Issue Date : 2025-01-22
Type : Chemical
Substance Number : 653
Certificate Number : CEP 2011-360 - Rev 02
Status : Valid
Issue Date : 2025-03-21
Type : Chemical
Substance Number : 653
Certificate Number : CEP 2017-133 - Rev 01
Status : Valid
Issue Date : 2024-02-19
Type : Chemical
Substance Number : 653
Certificate Number : CEP 2016-313 - Rev 01
Status : Valid
Issue Date : 2025-05-14
Type : Chemical
Substance Number : 653
Certificate Number : CEP 2006-229 - Rev 02
Status : Valid
Issue Date : 2024-07-25
Type : Chemical
Substance Number : 653
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registration Number : 230MF10014
Registrant's Address : 19 Pellinska Str. 83-200 Starogard Gdanski POLAND
Initial Date of Registration : 2018-01-30
Latest Date of Registration : 2019-03-19
Registration Number : 220MF10253
Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY
Initial Date of Registration : 2008-12-12
Latest Date of Registration : 2008-12-12
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Date of Issue : 2022-07-07
Valid Till : 2025-07-21
Written Confirmation Number : WC-0150
Address of the Firm : APIUnit-l,R.SNo50/1,Mukteswarapuram Village, Jaggaiahpet Mandal, NTRDistrict-521...
Date of Issue : 2023-07-24
Valid Till : 2026-08-23
Written Confirmation Number : WC-0381
Address of the Firm : Plot No. 98-99, Sector-1, Industrial Area Pithampur, Dhar-454775, Madhya Pradesh...
Date of Issue : 2022-06-29
Valid Till : 2025-02-07
Written Confirmation Number : WC-0123
Address of the Firm : Sy. Nos. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandai, Sangareddy District, T...
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm : Plot No. 99, MIDC Area - Dhatav Roha, Dist. Raigad, Roha, Raigad-402116, Maharas...
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : Korea United Pharmaceutical Co., Ltd.
Registration Date : 2019-01-24
Registration Number : 20181018-209-J-161(3)
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Str.83-200 Starogard Gdanski, Poland
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2019-01-11
Registration Number : 20181018-209-J-161(2)
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : Taejun Pharmaceutical Co., Ltd.
Registration Date : 2019-06-14
Registration Number : 20181018-209-J-161(4)
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : Hwail Pharmaceutical Co., Ltd.
Registration Date : 2018-12-03
Registration Number : 20181018-209-J-161(1)
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : IMCD Korea Co., Ltd.
Registration Date : 2018-10-18
Registration Number : 20181018-209-J-161
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Registrant Name : Wooshin Labotech Co., Ltd.
Registration Date : 2019-08-02
Registration Number : 20181018-209-J-161(5)
Manufacturer Name : Pharmaceutical Works Polphar...
Manufacturer Address : 19, Pelplinska Street. 83-200 Starogard Gdanski, Poland
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2021-06-29
Registration Number : 20210629-209-J-1043
Manufacturer Name : Cohance Lifesciences Limited
Manufacturer Address : RS 50/1, Mukteswarapuram Village, Jaggaiahpeta Mandal, Krishna District-521 175. Andh...
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
NDC Package Code : 12658-0622
Start Marketing Date : 1977-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
NDC Package Code : 12658-0448
Start Marketing Date : 1977-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
NDC Package Code : 12658-0624
Start Marketing Date : 1977-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (12kg/12kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 51014-7035
Start Marketing Date : 2009-08-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 48954-641
Start Marketing Date : 1997-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 48954-469
Start Marketing Date : 1986-06-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76420-165
Start Marketing Date : 2019-09-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51552-0613
Start Marketing Date : 2004-09-01
End Marketing Date : 2027-01-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-2007
Start Marketing Date : 2000-07-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 82393-207
Start Marketing Date : 2022-04-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
ANI will commercialize generic Fleqsuvy (baclofen) to treat spasticity from multiple sclerosis, offering relief from flexor spasms and pain, with significant therapeutic benefits.
Lead Product(s): Baclofen
Therapeutic Area: Neurology Brand Name: Fleqsuvy-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
Details : ANI will commercialize generic Fleqsuvy (baclofen) to treat spasticity from multiple sclerosis, offering relief from flexor spasms and pain, with significant therapeutic benefits.
Product Name : Fleqsuvy-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Details:
Baclofen is a GABA-ergic agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Lead Product(s): Baclofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2024
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Launches Baclofen Injection, USP
Details : Baclofen is a GABA-ergic agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Details:
Arbaclofen selectively activates GABA-B receptors to decrease presynaptic release of excitatory neurotransmitters while simultaneously decreasing excitability of the postsynaptic neuron.
Lead Product(s): Baclofen
Therapeutic Area: Genetic Disease Brand Name: STX209
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2023
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen selectively activates GABA-B receptors to decrease presynaptic release of excitatory neurotransmitters while simultaneously decreasing excitability of the postsynaptic neuron.
Product Name : STX209
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Details:
PXT3003 (baclofen) is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice a day for the treatment of Charcot-Marie-Tooth disease type 1A.
Lead Product(s): Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area: Genetic Disease Brand Name: PXT3003
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 (baclofen) is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice a day for the treatment of Charcot-Marie-Tooth disease type 1A.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2022
Details:
PXT3003 (baclofen) completed an international Phase III trial with positive topline results for the treatment of CharcotMarie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States.
Lead Product(s): Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area: Genetic Disease Brand Name: PXT3003
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PXT3003 (baclofen) completed an international Phase III trial with positive topline results for the treatment of CharcotMarie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States.
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Details:
Clinically meaningful magnitudes of improvement were observed on all three ABCFX subscales for 45% of individuals receiving high dose of arbaclofen vs 4% treated with placebo (P=0.00003), clearly demonstrating efficacy of STX209 (arbaclofen) in individuals with Fragile X.
Lead Product(s): Baclofen
Therapeutic Area: Genetic Disease Brand Name: STX209
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2022
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinically meaningful magnitudes of improvement were observed on all three ABCFX subscales for 45% of individuals receiving high dose of arbaclofen vs 4% treated with placebo (P=0.00003), clearly demonstrating efficacy of STX209 (arbaclofen) in individua...
Product Name : STX209
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Details:
New data from the ongoing Open-Label Phase III Extension Study of PXT3003 (baclofen), the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall Neuropathy Limitation Scale after 5 years of total trial time.
Lead Product(s): Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area: Genetic Disease Brand Name: PXT3003
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data from the ongoing Open-Label Phase III Extension Study of PXT3003 (baclofen), the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall Neuropathy Limitation Scale after 5 years of total...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Details:
Amneal is adding Saol’s experienced institutional commercial team for Lioresal that can be utilized to support product launches, including biosimilar products, filgrastim (biosimilar for Neupogen), pegfilgrastim (biosimilar for Neulasta) & bevacizumab (biosimilar for Avastin).
Lead Product(s): Baclofen
Therapeutic Area: Musculoskeletal Brand Name: Lioresal
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 01, 2022
Lead Product(s) : Baclofen
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
Details : Amneal is adding Saol’s experienced institutional commercial team for Lioresal that can be utilized to support product launches, including biosimilar products, filgrastim (biosimilar for Neupogen), pegfilgrastim (biosimilar for Neulasta) & bevacizumab ...
Product Name : Lioresal
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2022
Details:
The financing by Neovacs will support Pharnext operations and cash requirements, in particular the Phase III PREMIER pivotal study assessing its PTX3003 (baclofen) candidate in CMT1A, a rare debilitating peripheral neuropathy with currently no existing approved therapy.
Lead Product(s): Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area: Genetic Disease Brand Name: PXT3003
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Neovacs
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2022
Lead Product(s) : Baclofen,Naloxone Hydrochloride,Sorbitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Neovacs
Deal Size : $20.0 million
Deal Type : Financing
Pharnext Executes a Financing Agreement with Néovacs for EUR 20.7 Million Net to Further Develop ...
Details : The financing by Neovacs will support Pharnext operations and cash requirements, in particular the Phase III PREMIER pivotal study assessing its PTX3003 (baclofen) candidate in CMT1A, a rare debilitating peripheral neuropathy with currently no existing a...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2022
Details:
LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries.
Lead Product(s): Baclofen,Naltrexone Hydrochloride,Sorbitol
Therapeutic Area: Musculoskeletal Brand Name: Lyvispah
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2022
Lead Product(s) : Baclofen,Naltrexone Hydrochloride,Sorbitol
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spina...
Details : LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries.
Product Name : Lyvispah
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : HiCel acts as a strong dry binder. It facilitates low tablet friability & promotes rapid tablet disintegration.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel CE15 offers a superior mouthfeel with less chalkiness and gritness in chewable tablets and orally disintegrating tablets (ODTs).
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Guar Gum Excipient
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : HiCel MCC Spheres
Application : Co-Processed Excipients
Excipient Details : HiCel MCC Spheres are extremely versatile which are used for controlled release or sustained release formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel MCG is use in oral suspensions as a stabilizer. It is a good binder for tablets & excellent thickener as well.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Carboxymethyl cellulose sodium
Dosage Form : Tablet
Grade : Oral
Application : Co-Processed Excipients
Excipient Details : HiCel SMCC has unique combination which result in optimum compaction & superior flow properties.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Granulation
Excipient Details : HiCellac is used in direct compression & dry granulation suitable for low dose formulations where API content uniformity is critical.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Stargel is used in oral pharmaceuticals as a disintegrant in tablet and capsules formulations. It is also used as a suspending agent & stabilizer.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Sodium Starch Glycolate
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Baclofen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Baclofen manufacturer or Baclofen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Baclofen manufacturer or Baclofen supplier.
PharmaCompass also assists you with knowing the Baclofen API Price utilized in the formulation of products. Baclofen API Price is not always fixed or binding as the Baclofen Price is obtained through a variety of data sources. The Baclofen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Alphapharm Brand of Baclofen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alphapharm Brand of Baclofen, including repackagers and relabelers. The FDA regulates Alphapharm Brand of Baclofen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alphapharm Brand of Baclofen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Alphapharm Brand of Baclofen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Alphapharm Brand of Baclofen supplier is an individual or a company that provides Alphapharm Brand of Baclofen active pharmaceutical ingredient (API) or Alphapharm Brand of Baclofen finished formulations upon request. The Alphapharm Brand of Baclofen suppliers may include Alphapharm Brand of Baclofen API manufacturers, exporters, distributors and traders.
click here to find a list of Alphapharm Brand of Baclofen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Alphapharm Brand of Baclofen DMF (Drug Master File) is a document detailing the whole manufacturing process of Alphapharm Brand of Baclofen active pharmaceutical ingredient (API) in detail. Different forms of Alphapharm Brand of Baclofen DMFs exist exist since differing nations have different regulations, such as Alphapharm Brand of Baclofen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Alphapharm Brand of Baclofen DMF submitted to regulatory agencies in the US is known as a USDMF. Alphapharm Brand of Baclofen USDMF includes data on Alphapharm Brand of Baclofen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Alphapharm Brand of Baclofen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Alphapharm Brand of Baclofen suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Alphapharm Brand of Baclofen Drug Master File in Japan (Alphapharm Brand of Baclofen JDMF) empowers Alphapharm Brand of Baclofen API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Alphapharm Brand of Baclofen JDMF during the approval evaluation for pharmaceutical products. At the time of Alphapharm Brand of Baclofen JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Alphapharm Brand of Baclofen suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Alphapharm Brand of Baclofen Drug Master File in Korea (Alphapharm Brand of Baclofen KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Alphapharm Brand of Baclofen. The MFDS reviews the Alphapharm Brand of Baclofen KDMF as part of the drug registration process and uses the information provided in the Alphapharm Brand of Baclofen KDMF to evaluate the safety and efficacy of the drug.
After submitting a Alphapharm Brand of Baclofen KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Alphapharm Brand of Baclofen API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Alphapharm Brand of Baclofen suppliers with KDMF on PharmaCompass.
A Alphapharm Brand of Baclofen CEP of the European Pharmacopoeia monograph is often referred to as a Alphapharm Brand of Baclofen Certificate of Suitability (COS). The purpose of a Alphapharm Brand of Baclofen CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Alphapharm Brand of Baclofen EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Alphapharm Brand of Baclofen to their clients by showing that a Alphapharm Brand of Baclofen CEP has been issued for it. The manufacturer submits a Alphapharm Brand of Baclofen CEP (COS) as part of the market authorization procedure, and it takes on the role of a Alphapharm Brand of Baclofen CEP holder for the record. Additionally, the data presented in the Alphapharm Brand of Baclofen CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Alphapharm Brand of Baclofen DMF.
A Alphapharm Brand of Baclofen CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Alphapharm Brand of Baclofen CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Alphapharm Brand of Baclofen suppliers with CEP (COS) on PharmaCompass.
A Alphapharm Brand of Baclofen written confirmation (Alphapharm Brand of Baclofen WC) is an official document issued by a regulatory agency to a Alphapharm Brand of Baclofen manufacturer, verifying that the manufacturing facility of a Alphapharm Brand of Baclofen active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Alphapharm Brand of Baclofen APIs or Alphapharm Brand of Baclofen finished pharmaceutical products to another nation, regulatory agencies frequently require a Alphapharm Brand of Baclofen WC (written confirmation) as part of the regulatory process.
click here to find a list of Alphapharm Brand of Baclofen suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alphapharm Brand of Baclofen as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Alphapharm Brand of Baclofen API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Alphapharm Brand of Baclofen as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Alphapharm Brand of Baclofen and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alphapharm Brand of Baclofen NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Alphapharm Brand of Baclofen suppliers with NDC on PharmaCompass.
Alphapharm Brand of Baclofen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alphapharm Brand of Baclofen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alphapharm Brand of Baclofen GMP manufacturer or Alphapharm Brand of Baclofen GMP API supplier for your needs.
A Alphapharm Brand of Baclofen CoA (Certificate of Analysis) is a formal document that attests to Alphapharm Brand of Baclofen's compliance with Alphapharm Brand of Baclofen specifications and serves as a tool for batch-level quality control.
Alphapharm Brand of Baclofen CoA mostly includes findings from lab analyses of a specific batch. For each Alphapharm Brand of Baclofen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alphapharm Brand of Baclofen may be tested according to a variety of international standards, such as European Pharmacopoeia (Alphapharm Brand of Baclofen EP), Alphapharm Brand of Baclofen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alphapharm Brand of Baclofen USP).